<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1506233808
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2014
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PALETA 75mg film-coated tablets
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CLOPIDOGREL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        75
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        91.90
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="PHARMATHEN INTERNATIONAL" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            PHARMATHEN INTERNATIONAL
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        B01AC04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Pharmacotherapeutic group: Paleta contains the active substance Clopidogrel, a platelet aggregation blocker. Platelets are very small structures which clump together (aggregate) during blood clotting. By preventing formation of blood clots (thrombi) in hardened blood vessels, Clopidogrel reduces the risk of strokes or heart attacks. Therapeutic indications: Paleta is used if you have hardening of the arteries (atherosclerosis), and you have either: - had a recent heart attack (myocardial infarction) or previous stroke, or - You have a condition which causes disturbed blood flow in arms or legs due to blockade of the blood vessels (peripheral arterial disease).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a. Do not take Paleta:</strong></p><p>- If you are allergic to Clopidogrel or any of the other ingredients of Paleta (listed in section 6 &lsquo;What Paleta contains&rsquo;).</p><p>- If you have a medical condition that is currently causing bleeding such as a stomach ulcer or bleeding within the brain.</p><p>- If you have severe liver disease.</p><p><strong>b. Take special care with Paleta: </strong></p><p>Tell your doctor before you start taking this medicine:</p><p>&bull; If you are at increased risk of bleeding such as: -Any condition (e.g. stomach ulcer) or blood disorder that makes you prone to internal bleeding (inside tissues, organs).</p><p>-Recent serious injury.</p><p>-Surgery (including dental), recent or due in the next 7 days.</p><p>&bull; If you have had a clot in an artery of your brain (ischaemic stroke) which occurred within the last 7 days.</p><p>&bull; If you have kidney or liver disease.</p><p>&bull; Clopidogrel is not intended for use in children or adolescents less than 18 years of age. If you are not sure if any of the above applies to you, talk to your doctor or pharmacist before taking Paleta tablets.</p><p><strong>c. Using other medicines, herbal or dietary supplements: </strong></p><p>Tell your doctor or pharmacist if you are using or have recently used any other medicines, including medicines obtained without a prescription, including herbal medicines. This is because some medicines can increase the chance of you getting side effects, when taken with Paleta tablets. Tell your doctor if you are taking any of the following medicines:</p><p>&bull; The medicines that contain any of the following active substances (which may increase the risk of bleeding):</p><p>- Oral anticoagulants (e.g. warfarin), which should not be used together with Paleta.</p><p>- Heparin, abciximab, eptifibatide, tirofiban and other medicines used to prevent blood clotting.</p><p>- Alteplase and streptokinase, used to break down blood clots.</p><p>- Non-steroidal anti-inflammatory drugs (NSAIDs), used to treat fever, pain and inflammation of muscles or joints (e.g. ibuprofen, diclofenac, naproxen).</p><p>- Proton pump inhibitors or cimetidine, medicines to treat upset stomach. Acetylsalicylic acid (an NSAID) may be used if prescribed, or occasionally up to 1000 mg in 24 h. However, discuss with your doctor its prolonged use in other circumstances.</p><p><strong>d. Taking Paleta with food and drink: </strong></p><p>You can take Paleta with food or without food.</p><p><strong>e. Pregnancy and breast-feeding: </strong></p><p>It is not recommended to use this medicine during pregnancy.</p><p>If you are pregnant or think you might be pregnant, tell your doctor before treatment start.</p><p>If you become pregnant while taking Paleta, tell your doctor immediately.</p><p>You should stop breast-feeding while taking Paleta, as it is not known if Clopidogrel passes into breast milk.</p><p><strong>f.Driving and using machines: </strong></p><p>Paleta is unlikely to affect your ability to drive or use machines</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Paleta exactly as your doctor has told you.</p><p>You should check with your doctor or pharmacist if you are not sure.</p><p>The usual dose is one 75 mg tablet daily, every day at the same time.</p><p>Take the tablet(s) with some liquid, with or without food.</p><p><strong>a. If you take more Paleta than you should </strong></p><p>Contact your doctor or the nearest emergency department immediately because of the increased risk of bleeding.</p><p>Take the medicine pack with you. This is so the doctor knows what you have taken.</p><p><strong>b. If you forget to take Paleta </strong></p><p>If you forget to take Paleta, but remember within 12 hours of your usual time, take your tablet straightaway, then take your next tablet at the usual time.</p><p>If you forget for more than 12 hours, skip the missed dose, then take the next tablet at the usual time.</p><p>Do not take a double dose to make up for a forgotten tablet.</p><p><strong>c. If you stop taking Paleta </strong></p><p>You should take Paleta as long as your doctor prescribes it.</p><p>Do not stop the treatment without discussing it with your doctor first.</p><p>If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Paleta can cause side effects, although not everybody gets them. Side effects may occur with certain frequencies, which are defined as follows:</p><table border="1" cellspacing="1" cellpadding="1" style="width:589px"><tbody><tr><td style="width:290px">Very common:</td><td style="width:296px">affects more than 1 user in 10</td></tr><tr><td style="width:290px">Common:</td><td style="width:296px">affects 1 to 10 users in 100</td></tr><tr><td style="width:290px">Uncommon:</td><td style="width:296px">affects 1 to 10 users in 1,000</td></tr><tr><td style="width:290px">Rare:</td><td style="width:296px">affects 1 to 10 users in 10,000</td></tr><tr><td style="width:290px">Very rare:</td><td style="width:296px">affects less than 1 user in 10,000</td></tr><tr><td style="width:290px">Not known:</td><td style="width:296px">frequency cannot be estimated from the available date</td></tr></tbody></table><p>Stop taking Paleta tablets &amp; contact your doctor immediately if you notice any of the following very rare serious side effects:</p><p>- Decrease of some blood cells: fever, signs of infection or extreme tiredness.</p><p>- Liver problems: yellowing of the skin and/or the eyes (jaundice), bleeding under the skin as red pinpoint dots, confusion.</p><p>- Allergic reactions: swelling of your lips, face, throat or tongue, skin rash, itching and blistering.</p><p>A very common side effect is bleeding, which may appear as: - Bruising and haematoma.</p><p>- Nose bleed, blood in the urine.</p><p>- Bleeding in the stomach or bowels or less frequently in the eye, head, lung or joints. If you cut or injure yourself, it may take longer than usual for bleeding to stop. This is linked to the way your medicine works as it prevents the ability of blood clots to form. For minor cuts and injuries e.g., cutting yourself, shaving, this is usually of no concern. However, if you are concerned by your bleeding, you should contact your doctor straightaway.</p><p><strong>Other side effects:</strong></p><p><strong>Common side effects: </strong></p><p>- Abdominal pain, indigestion or heartburn</p><p>- Diarrhea Uncommon side effects:</p><p>- Headache, dizziness</p><p>- Stomach ulcer</p><p>- Vomiting, nausea</p><p>- Constipation, excessive gas in stomach or intestines</p><p>- Skin rash, itching</p><p><strong>Rare side effects: </strong></p><p>- vertigo</p><p><strong>Very rare side effects: </strong></p><p>- Fever</p><p>- Yellowing of the skin and/or the eyes (jaundice).</p><p>- Severe abdominal pain with or without back pain, pain in joints or muscles.</p><p>- Skin blisters and allergy.</p><p>- Swelling or inflammation lips, face, throat or tongue.</p><p>- breathing difficulties, sometimes with cough.</p><p>- Decrease in blood pressure.</p><p>- Confusion, hallucinations.</p><p>- Taste disorders. In addition, your doctor may identify changes in your blood or urine test results. If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.</p><p>Store below 30&ordm;C in the original carton.</p><p>Do not use Paleta after the expiry date which is stated on the carton.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- The active substance is Clopidogrel. Each film-coated Paleta tablet contains 75 mg of Clopidogrel (as besilate).</p><p>- The other ingredients are: Cellulose microcrystalline, Spray-dried Mannitol (Mannogem EZ), Hydroxypropylcellulose, Crospovidone,Citric acid, Polyethylene glycol 6000, Stearic acid (Speziol L2SM), Talc, OpadryIIPink 32K14834.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Paleta tablets are film-coated tablets for oral use. The tablets are round, biconvex with
pink colour.
Paleta 75 mg is available in pack sizes of 28 tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SPIMACO</p><p>AlQassim pharmaceutical plant Saudi Pharmaceutical Industries &amp; Medical Appliance Corporation.</p><p>Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                May 2012. 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>تحتوي&nbsp;أقراص&nbsp;باليتا&nbsp;على&nbsp;دواء&nbsp;يسمى&nbsp;كلوبيدوجريل&nbsp;والذي&nbsp;يستخدم&nbsp;كحاصر&nbsp;لتكدس&nbsp;الصفيحات.&nbsp;الصفيحات&nbsp;هي&nbsp;بنى&nbsp;صغيرة&nbsp;جدا&nbsp;قد&nbsp;تتجمع&nbsp;مع&nbsp;بعضها&nbsp;البعض)تتكدس(&nbsp;في&nbsp;أثناء&nbsp;عملية&nbsp;تخثر&nbsp;الدم.&nbsp;وقد&nbsp;يؤدي&nbsp;استخدام&nbsp;كلوبيدوجريل&nbsp;إلي&nbsp;تقليل&nbsp;خطر&nbsp;الإصابة&nbsp;</p><p>بالسكتات&nbsp;أو&nbsp;النوبات&nbsp;القلبية&nbsp;عن&nbsp;طريق&nbsp;منع&nbsp;تكون&nbsp;الجلطات&nbsp;الدموية&nbsp;)الخثرات)&nbsp;في&nbsp;الأوعية&nbsp;الدموية&nbsp;المتيبسة.&nbsp;</p><p>الدواعي العلاجية:</p><p>يستخدم باليتا إذا كنت تعاني من تصلب الشرايين (التصلب العصيدي) وتعاني من إما:</p><p>- نوبرة قلبية حدثت لك حديثا (احتشاء عضلة القلب) أو سكتة سابقة أو</p><p>- أنك قد أصبحت بحالة مرضية أدت إلى حدوث اضطراب لتدفق الدم إلى الأعضاء أو السيقان وذلك لانسداد الأوعية الدموية (المر الشريامي الطرفي).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>أ- لاتستعمل هذا الدواء واستشر الطبيب المعالج إذا:</strong></p><ul><li><p>كان&nbsp;لديك&nbsp;فرط&nbsp;تحسس&nbsp;لمادة&nbsp;كلوبيدوجريل&nbsp;أو&nbsp;لأي&nbsp;من&nbsp;مكونات&nbsp;أقراص&nbsp;باليتا&nbsp;والمذكورة&nbsp;في&nbsp;الفقرة&nbsp;رقم&nbsp;6.&nbsp;</p></li><li><p>إذا&nbsp;كنت&nbsp;تعاني&nbsp;من&nbsp;ظرف&nbsp;طبي&nbsp;في&nbsp;الوقت&nbsp;الحالي&nbsp;يسبب&nbsp;نزيف&nbsp;دموي&nbsp;كقرحة&nbsp;المعدة&nbsp;أو&nbsp;نزيف&nbsp;في&nbsp;المخ.&nbsp;</p></li><li><p>إذا&nbsp;كنت&nbsp;تعاني&nbsp;من&nbsp;مرض&nbsp;شديد&nbsp;بالكبد.&nbsp;</p></li></ul><p><strong>ب- الاحتياطات الخاصة عند تناول باليتا:</strong></p><p><strong>يجب التأكد من الطبيب قبل تناول هذا الدواء إذا:</strong></p><ul><li>كنت معرض لزيادة خطر حدوث النزيف كما في الحالات التالية:</li></ul><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; -أي من الحالات المرضية (كقرحة المعدة) أو اضطرابات الدم والتي تجعلك عرضة للنزيف الداخلي (الأنسجة و الأعضاء الداخلية).</p><p>- إصابة حديثة وخطيرة.</p><p>- الجراحة (وتتضمن جراحات الأسنان) سواء كانت حديثة أو حدثت خلال 7 أيام.</p><ul><li>إذا كنت تعاني من حدوث جلطة في أحد شرايين المخ (سكته إقفارية)، بحيث تكون قد حدثت خلال 7 أيام ماضية.</li><li>إذا كنت تعاني من مرض في الكلى أو الكبد.</li><li>لايجب استخدام كلوبيدوجريل في حالة الأطفال أو المراهقين الأقل من 18 عام.</li></ul><p>تحدث مع الطبيب المعالج أو الصيدلي قبل أن تتناول باليتا إذا لم تكن متأكدا من أن أي من الحالات السابقة متعلقة بك.</p><p><strong>ج- التداخلات الدوائية من أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية:</strong></p><p>أخبر الطبيب المعالج أو الصيدلي إذا كنت تتناول أو&nbsp; قد تناولت مؤخرا أي أدوية أخرى بما في ذلك الأدوية التي تعطى بدون وصفة طبية وتشمل العلاج بالأعشاب.</p><p>وذلك نظرا لأن بعض الأدوية قد تزيد من فرصة حدوث الأثار الجانبية لديك إذا تم تناولها مع أقراص باليتا.</p><p><strong>قم بإخبار الطبيب المعالج إذا كنت تتناول أي من الأدوية التالي ذكرها:</strong></p><ul><li>الأدوية التي تحتوي على أي من المواد الفعالة التالية ( والتي من الممكن أن تزيد من خطر حدوث النزيف):</li></ul><p>- مضادات التخثر (مثل وارفرين) والتي لا يجب أن تستخدم مع باليتا.</p><p>- الهيبارين، إبسيكسيماب، إبتيفيباتيد، تيروفيبان والأدوية الأخرى التي تمنع تجلط الدم.</p><p>- ألتيبلاز وستروبتوكينيز والتي تستخدم في إذابة الجلطات.</p><p>-مضادات&nbsp;الالتهاب&nbsp;غير&nbsp;الستيرويدية&nbsp;و&nbsp;التي&nbsp;تستخدم&nbsp;في&nbsp;علاج&nbsp;حالات&nbsp;الألم&nbsp;والتهاب&nbsp;العضلات&nbsp;و&nbsp;المفاصل (مثل إيبوبروفين وديكلوفيناك ونبروكسين).</p><p>- العقاقير المثبطة لمضخة البروتون أو سيميتيدين، أدوية تستخدم لعلاج اعتلال المعدة.</p><p>يمكن استخدام أسيتيل سالسيليك أسيد كأحد مضادات الإلتهاب غير الستيرويدية لو تم وصفه أو أحيانا حتى جرعة 1000 ملجم في اليوم. ولكن يجب مناقشة الطبيب في حالة استخدامه لفترة زمنية أطول نتيجة لظروف مرضية أخرى.</p><p><strong>د- تناول&nbsp;باليتا&nbsp;مع&nbsp;الطعام&nbsp;والشراب:</strong></p><p>يمكن&nbsp;تناول&nbsp;أقراص&nbsp;باليتا&nbsp;مع&nbsp;الطعام&nbsp;أو&nbsp;بدونه.&nbsp;</p><p><strong>هـ- لحمل&nbsp;والرضاعة:</strong></p><p>لايوصى باستخدام هذا الدواء أثناء الحمل.</p><p>إذا كنت حامل أو تفكرين في إمكانية حدوث الحمل، يجب أن تخبري الطبيب قبل بدء العلاج. يجب أن تخبري الطبيب في الحال في حالة ما إذا حدث الحمل في أثناء تناول باليتا.</p><p>يجب أن توقفي الرضاعة الطبيعية في أثناء تناول باليتا، إذ أنه من غير المعلوم ما إذا كان كلوبيدوجريل يفرز في حليب الأم أم لا.</p><p><strong>و- تأثير باليتا على القيادة واستخدام الآلات:</strong></p><p>من غير المحتمل أن يؤثر تناول باليتا على قدرتك على القيادة أو استخدام الآلات.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يجب تناول جرعة من أقراص باليتا حسب تعليمات الطبيب المعالج. يجب أن تراجع الطبيب المعالج أو الصيدلي إذا لم تكن متأكدا.</p><p>الجرعة المعتادة هي قرص واحد 75 ملجم يومياً، على أن يتم تكرار تناول الدواء يوميا في نفس الميعاد.</p><p>يجب تناول القرص أو الأقراص مع كمية مناسبة من الماء مع الطعام أو بدونه.</p><p><strong>أ- الجرعة الزائدة من باليتا</strong></p><p>استشر الطبيب المعالج أو أقرب قسم طوارئ في الحال وذلك بسبب زيادة خطر حدوث نزيف خذ معك علبة الدواء لكي يتمكن الطبيب من معرفة الدواء الذي تناولته.</p><p><strong>ب- نسيان تناول جرعة باليتا</strong></p><p>إذا نسيت تناول جرعة من أقراص باليتا وتذكرت ذلك خلال 12 ساعة من ميعاد جرعتك المعتادة، فيجب أن تتناول الجرعة في الحال وقت تذكرها، ثم تناول الجرعة التالية في ميعادها المعتاد. إذا نسيت الجرعة ولم تتذكرها خلال 21 ساعة من ميعادها،</p><p>لا تتناول الجرعة المنسية ثم تناول الجرعة التالية في ميعادها المعتاد. لا تتناول جرعة مضاعفة لتعويض الجرعة المنسية.</p><p><strong>ج- التوقف عن تناول باليتا</strong></p><p>يجب أن تكمل مدة العلاج المحددة لك من قبل الطبيب المعالج.</p><p>لا تتوقف عن تناول العلاج دون مناقشة الطبيب أولا.</p><p>إذا كانت لديك أي أسئلة أو استفسارات أخرى، استشر الطبيب المعالج أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل&nbsp;جميع&nbsp;الأدوية&nbsp;الأخرى،&nbsp;قد&nbsp;يسبب&nbsp;باليتا&nbsp;أعراض&nbsp;جانبية&nbsp;عند&nbsp;استخدامه،&nbsp;وبالرغم&nbsp;من&nbsp;ذلك&nbsp;ليس&nbsp;من&nbsp;الضروري&nbsp;أن&nbsp;تظهر&nbsp;هذه&nbsp;الأعراض&nbsp;في&nbsp;جميع&nbsp;المرضى.&nbsp;</p><p>قد&nbsp;تحدث&nbsp;الأعراض&nbsp;الجانبية&nbsp;بمعدلات&nbsp;معينة&nbsp;و&nbsp;التي&nbsp;يمكن&nbsp;تحديدها&nbsp;كالتالي:&nbsp;</p><table border="1"><tbody><tr><td><p>تؤثر&nbsp;على&nbsp;أكثر&nbsp;من&nbsp;1&nbsp;لكل&nbsp;10&nbsp;مستخدمين&nbsp;للدواء&nbsp;</p></td><td><p>شائعة&nbsp;جدا&nbsp;&nbsp;</p></td></tr><tr><td><p>تؤثر&nbsp;على&nbsp;1&nbsp;إلى&nbsp;10&nbsp;لكل&nbsp;100&nbsp;مستخدم&nbsp;للدواء&nbsp;</p></td><td><p>شائعة&nbsp;</p></td></tr><tr><td><p>تؤثر&nbsp;على&nbsp;1&nbsp;إلى&nbsp;10&nbsp;لكل&nbsp;1000&nbsp;مستخدم&nbsp;للدواء&nbsp;</p></td><td><p>غير&nbsp;شائعة&nbsp;</p></td></tr><tr><td><p>تؤثر&nbsp;على&nbsp;1&nbsp;إلى&nbsp;10&nbsp;لكل&nbsp;10000&nbsp;مستخدم&nbsp;للدواء&nbsp;</p></td><td><p>نادرة&nbsp;&nbsp;</p></td></tr><tr><td><p>تؤثر&nbsp;على&nbsp;أقل&nbsp;من&nbsp;1&nbsp;لكل&nbsp;10000&nbsp;مستخدم&nbsp;للدواء&nbsp;</p></td><td><p>نادرة&nbsp;جدا&nbsp;&nbsp;</p></td></tr><tr><td><p>لايمكن&nbsp;تقدير&nbsp;معدل&nbsp;الحدوث&nbsp;بناءا&nbsp;على&nbsp;المعلومات&nbsp;المتوفرة&nbsp;</p></td><td><p>غير&nbsp;معلوم&nbsp;&nbsp;</p></td></tr></tbody></table><p>توقف عن تناول أقراص باليتا واتصل بطبيبك الخاص في الحال إذا لاحظت أي من الأعراض النادرة الحدوث جدا و الخطرة التالية:</p><p>- نقص في عدد بعض خلايا الدم: حمى، ظهور علامات حدوث عدوى أو تعب شديد.</p><p>- مشكلات الكبد: اصفرار لون الجلد و/ أو العيون (اليرقان)، نزيف تحت الجلد على هيئة نقاط حمراء دقيقة جدا أو ارتباك.</p><p>- تفاعلات أرجية: تورم في الشفتين، الوجه، الحلق أو اللسان، طفح جلدي، حكة وتنفط.</p><p><strong>النزيف وهو عرض جانبي شائع الحدوث جدا، وقد يظهر على هيئة:</strong></p><p>-تكدم و ورم دموي.</p><p>- نزيف الأنف أو دم في البول.</p><p>- نزيف المعدة أو الأمعاء أو بشكل أقل حدوثا نزيف العين والرأس و الرئة و المفاصل.</p><p>في حال ما إذا أحدثت قطع أو إصابة لنفسك، من الممكن أن يستمر النزيف لفترة أطول من المعتاد دون توقف. وهذا يرجع</p><p>&nbsp;إلى طريقة عمل دواؤك الذي تتناوله حيث أنه يمنع تكوين الجلطات الدموية. في حالات الجروح والإصابات البسيطة كأن</p><p>تجرح نفسك أو أثناء الحلاقة، عادة ما يكون الأمر بسيط وقليل الخطورة. في حالة إحساسك بالخطورة نتيجة إصابتك بالنزيف، يجب أن تتصل بطبيبك المعالج مباشرة.</p><p><strong>الأعراض&nbsp;الجانبية الأخرى:</strong></p><p><strong>الأعراض&nbsp;الجانبية الشائعة الحدوث:</strong></p><p>- ألم البطن، عسر الهضم أو حرقة الفؤاد.</p><p>- الإسهال.</p><p><strong>الأعراض&nbsp;الجانبية غير الشائعة الحدوث:</strong></p><p>- الصداع والدوخة.</p><p>- قرحة المعدة.</p><p>- القيء والغثيان.</p><p>- إمساك و غازات مفرطة في المعدة أو الأمعاء.</p><p>- طفح جلدي و حكة.</p><p><strong>الأعراض&nbsp;الجانبية النادرةالحدوث:</strong></p><p>- دوار.</p><p><strong>الأعراض&nbsp;الجانبية الشائعة الحدوث جدا:</strong></p><p>- حمى.</p><p>- اصفرار&nbsp;لون&nbsp;الجلد&nbsp;و/&nbsp;أو&nbsp;العيون&nbsp;)اليرقان(.&nbsp;</p><p>- ألم&nbsp;البطن&nbsp;الشديد&nbsp;مع&nbsp;أو&nbsp;بدون&nbsp;ألم&nbsp;الظهر،&nbsp;ألم&nbsp;المفاصل&nbsp;أو&nbsp;العضلات.&nbsp;</p><p>- نفطات&nbsp;جلدية&nbsp;و&nbsp;أرجية.&nbsp;</p><p>- تورم&nbsp;في&nbsp;الشفتين،&nbsp;الوجه،&nbsp;الحلق،&nbsp;أو&nbsp;اللسان.&nbsp;</p><p>- صعوبات&nbsp;في&nbsp;التنفس&nbsp;و&nbsp;في&nbsp;بعض&nbsp;الأحيان&nbsp;كحة.&nbsp;</p><p>- انخفاض&nbsp;ضغط&nbsp;الدم.&nbsp;</p><p>- ارتباك&nbsp;و&nbsp;هلاوس.&nbsp;</p><p>- اضطرابات&nbsp;التذوق.&nbsp;</p><p>بالإضافة&nbsp;إلى&nbsp;ذلك،&nbsp;قد&nbsp;يلاحظ&nbsp;طبيبك&nbsp;المعالج&nbsp;تغيرات&nbsp;في&nbsp;نتائج&nbsp;اختبارات&nbsp;تحليل&nbsp;الدم&nbsp;أو&nbsp;البول&nbsp;الخاصة&nbsp;بك.&nbsp;</p><p>استشر&nbsp;الطبيب&nbsp;المعالج&nbsp;أو&nbsp;الصيدلي&nbsp;اذا&nbsp;ازدادت&nbsp;الأعراض&nbsp;الجانبية&nbsp;سوءاً&nbsp;أو&nbsp;إذا&nbsp;لاحظت&nbsp;أي&nbsp;أعراض&nbsp;جانبية&nbsp;أخرى&nbsp;غير&nbsp;مذكورة&nbsp;بهذه&nbsp;النشرة&nbsp;الطبية.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ&nbsp;بعيدا&nbsp;عن&nbsp;متناول&nbsp;الأطفال.&nbsp;</p><p>يحفظ&nbsp;في&nbsp;درجة&nbsp;حرارة&nbsp;أقل&nbsp;من&nbsp;30&nbsp;درجة&nbsp;مئوية&nbsp;في&nbsp;عبوته&nbsp;الأصلية.&nbsp;</p><p>لا&nbsp;تستخدم&nbsp;باليتا&nbsp;بعد&nbsp;انتهاء&nbsp;تاريخ&nbsp;الصلاحية&nbsp;المدون&nbsp;على&nbsp;العبوة.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة&nbsp;الفعالة&nbsp;كلوبيدوجريل.&nbsp;يحتوي&nbsp;كل&nbsp;قرص&nbsp;مغلف&nbsp;بطبقة&nbsp;رقيقة&nbsp;من&nbsp;باليتا&nbsp;على&nbsp;75&nbsp;ملجم&nbsp;من&nbsp;مادة&nbsp;كلوبيدوجريل&nbsp;(على&nbsp;هيئة&nbsp;بيسايلت).&nbsp;</p><p>المواد&nbsp;الغير&nbsp;فعالة:&nbsp;مايكروكريستالين&nbsp;سليولوز،&nbsp;رزاز&nbsp;المنيتول&nbsp;المجفف&nbsp;)مانوجيم&nbsp; (EZهيدروكسي&nbsp;بروبايل&nbsp;سليولوز،&nbsp;كروسبوفيدون،&nbsp;حمض&nbsp;الستريك،&nbsp;بولي&nbsp;إيثيلين&nbsp;جليكول&nbsp;6000،&nbsp;حمض&nbsp;الإستياريك&nbsp; )إسبيزيول&nbsp;L2SM&nbsp;(،&nbsp;تلك&nbsp;و&nbsp;أوبيدراي&nbsp;وردي&nbsp;32K&nbsp;14834.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>أقراص باليتا هي عبارة عن أقراص مغلفة بطبقة رقيقة للتناول عن طريق الفم وهي أقراص مستديرة و محدبة الوجهين لونها وردي. تتوفر باليتا 75 ملجم في عبوات تحتوي على 28 قرص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>الدوائية&nbsp;</p><p>مصنع&nbsp;الأدوية&nbsp;بالقصيم،&nbsp;</p><p>الشركة&nbsp;السعودية&nbsp;للصناعات&nbsp;الدوائية&nbsp;والمستلزمات&nbsp;الطبية،&nbsp;</p><p>المملكة&nbsp;العربية&nbsp;السعودية.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مايو 2012.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Paleta 75mg FC Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 75 mg of clopidogrel (as besilate).
For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
Pink, round, biconvex filmcoated tablets.
Number of tablets in Pack. 28.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clopidogrel is indicated in adults for the prevention of atherothrombotic events in:<br />&bull; Patients suffering from myocardial infarction (from a few days until less than 35 days),<br />ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial<br />disease.<br />For further information please refer to section 5.1.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&bull; Adults and elderly<br />Clopidogrel should be given as a single daily dose of 75 mg with or without food.<br />&bull; Pharmacogenetics</p><p>CYP2C19 poor metaboliser status is associated with diminished response to clopidogrel. The<br />optimal dose regimen for poor metabolisers has yet to be determined (see section 5.2).<br />&bull; Paediatric patients<br />The safety and efficacy of clopidogrel in children and adolescents have not yet been<br />established.<br />&bull; Renal impairment<br />Therapeutic experience is limited in patients with renal impairment (see section 4.4).<br />&bull; Hepatic impairment<br />Therapeutic experience is limited in patients with moderate hepatic disease who may have<br />bleeding diatheses (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to the active substance or to any of the excipients.
• Severe liver impairment.
• Active pathological bleeding such as peptic ulcer or intracranial haemorrhage.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Bleeding and haematological disorders</em><br />Due to the risk of bleeding and haematological adverse reactions, blood cell count<br />determination and/or other appropriate testing should be promptly considered whenever<br />clinical symptoms suggestive of bleeding arise during the course of treatment (see section 4.8).<br />As with other antiplatelet agents, clopidogrel should be used with caution in patients who may<br />be at risk of increased bleeding from trauma, surgery or other pathological conditions and in<br />patients receiving treatment with ASA, heparin, glycoprotein IIb/IIIa inhibitors or non-steroidal<br />anti-inflammatory drugs (NSAIDs) including Cox-2 inhibitors. Patients should be followed</p><p>carefully for any signs of bleeding including occult bleeding, especially during the first weeks<br />of treatment and/or after invasive cardiac procedures or surgery. The concomitant<br />administration of clopidogrel with oral anticoagulants is not recommended since it may<br />increase the intensity of bleedings (see section 4.5).<br />If a patient is to undergo elective surgery and antiplatelet effect is temporarily not desirable,<br />clopidogrel should be discontinued 7 days prior to surgery. Patients should inform physicians<br />and dentists that they are taking clopidogrel before any surgery is scheduled and before any<br />new medicinal product is taken. Clopidogrel prolongs bleeding time and should be used with<br />caution in patients who have lesions with a propensity to bleed (particularly gastrointestinal<br />and intraocular).<br />Patients should be told that it might take longer than usual to stop bleeding when they take<br />clopidogrel (alone or in combination with ASA), and that they should report any unusual<br />bleeding (site or duration) to their physician.<br /><em>Thrombotic Thrombocytopenic Purpura (TTP)</em><br />Thrombotic Thrombocytopenic Purpura (TTP) has been reported very rarely following the use<br />of clopidogrel, sometimes after a short exposure. It is characterised by thrombocytopenia and<br />microangiopathic haemolytic anaemia associated with either neurological findings, renal<br />dysfunction or fever. TTP is a potentially fatal condition requiring prompt treatment including<br />plasmapheresis.<br /><em>Recent ischaemic stroke</em><br />In view of the lack of data, clopidogrel cannot be recommended during the first 7 days after<br />acute ischaemic stroke.<br /><em>Cytochrome P450 2C19 (CYP2C19)</em><br />Pharmacogenetics: Based on literature data, patients with genetically reduced CYP2C19<br />function have lower systemic exposure to the active metabolite of clopidogrel and diminished</p><p>antiplatelet responses, and generally exhibit higher cardiovascular event rates following<br />myocardial infarction than do patients with normal CYP2C19 function (see section 5.2).<br />Since clopidogrel is metabolised to its active metabolite partly by CYP2C19, use of medicinal<br />products that inhibit the activity of this enzyme would be expected to result in reduced drug<br />levels of the active metabolite of clopidogrel. The clinical relevance of this interaction is<br />uncertain. As a precaution concomitant use of medicinal products that inhibit CYP2C19 should<br />be discouraged (see section 4.5 for a list of CYP2C19 inhibitors, see also section 5.2).<br /><em>Renal impairment</em><br />Therapeutic experience with clopidogrel is limited in patients with renal impairment. Therefore<br />clopidogrel should be used with caution in these patients (see section 4.2).<br /><em>Hepatic impairment</em><br />Experience is limited in patients with moderate hepatic disease who may have bleeding<br />diatheses. Clopidogrel should therefore be used with caution in this population (see section<br />4.2).<br /><em>Excipients</em><br />Paleta contains lactose. Patients with rare hereditary problems of galactose intolerance, the<br />Lapp lactase deficiency or glucose galactose malabsorption should not take this medicinal<br />product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Oral anticoagulants: the concomitant administration of clopidogrel with oral anticoagulants<br />is not recommended since it may increase the intensity of bleedings (see section 4.4).<br />Glycoprotein IIb/IIIa inhibitors: clopidogrel should be used with caution in patients who</p><p>receive concomitant glycoprotein IIb/IIIa inhibitors (see section 4.4).<br /><em>Acetylsalicylic acid (ASA):</em> ASA did not modify the clopidogrel-mediated inhibition of ADPinduced<br />platelet aggregation, but clopidogrel potentiated the effect of ASA on collageninduced<br />platelet aggregation. However, concomitant administration of 500 mg of ASA twice<br />a day for one day did not significantly increase the prolongation of bleeding time induced by<br />clopidogrel intake. A pharmacodynamic interaction between clopidogrel and acetylsalicylic<br />acid is possible, leading to increased risk of bleeding. Therefore, concomitant use should be<br />undertaken with caution (see section 4.4). However, clopidogrel and ASA have been<br />administered together for up to one year (see section 5.1).<br /><em>Heparin:</em> in a clinical study conducted in healthy subjects, clopidogrel did not necessitate<br />modification of the heparin dose or alter the effect of heparin on coagulation. Coadministration<br />of heparin had no effect on the inhibition of platelet aggregation induced by<br />clopidogrel. A pharmacodynamic interaction between clopidogrel and heparin is possible,<br />leading to increased risk of bleeding. Therefore, concomitant use should be undertaken with<br />caution (see section 4.4).<br /><em>Thrombolytics</em>: the safety of the concomitant administration of clopidogrel, fibrin or nonfibrin<br />specific thrombolytic agents and heparins was assessed in patients with acute<br />myocardial infarction. The incidence of clinically significant bleeding was similar to that<br />observed when thrombolytic agents and heparin are co-administered with ASA (see section<br />4.8)<br /><em>NSAIDs: </em>in a clinical study conducted in healthy volunteers, the concomitant administration<br />of clopidogrel and naproxen increased occult gastrointestinal blood loss. However, due to the<br />lack of interaction studies with other NSAIDs it is presently unclear whether there is an<br />increased risk of gastrointestinal bleeding with all NSAIDs. Consequently, NSAIDs<br />including Cox-2 inhibitors and clopidogrel should be co-administered with caution (see</p><p>section 4.4).<br /><em>Other concomitant therapy:</em><br />Since clopidogrel is metabolised to its active metabolite partly by CYP2C19, use of<br />medicinal products that inhibit the activity of this enzyme would be expected to result in<br />reduced drug levels of the active metabolite of clopidogrel. The clinical relevance of this<br />interaction is uncertain. As a precaution concomitant use of medicinal products that inhibit<br />CYP2C19 should be discouraged (see sections 4.4 and 5.2).<br />Medicinal products that inhibit CYP2C19 include omeprazole and esomeprazole,<br />fluvoxamine, fluoxetine, moclobemide, voriconazole, fluconazole, ticlopidine, ciprofloxacin,<br />cimetidine, carbamazepine, oxcarbazepine and chloramphenicol.<br />Proton Pump Inhibitors (PPI): In a crossover clinical study, clopidogrel (300-mg loading<br />dose followed by 75 mg/day) alone and with omeprazole (80 mg at the same time as<br />clopidogrel) were administered for 5 days. The exposure to the active metabolite of<br />clopidogrel was decreased by 45% (Day 1) and 40% (Day 5) when clopidogrel and<br />omeprazole were administered together. Mean inhibition of platelet aggregation (IPA) with 5<br />&mu;M ADP was diminished by 39% (24 hours) and 21% (Day 5) when clopidogrel and<br />omeprazole were administered together. In another study it was shown that administering<br />clopidogrel and omeprazole 12 hours apart did not prevent their interaction that is likely to<br />be driven by the inhibitory effect of omeprazole on CYP2C19. Esomeprazole is expected to<br />give a similar interaction with clopidogrel.<br />Inconsistent data on the clinical implications of this pharmacokinetic<br />(PK)/pharmacodynamic (PD) interaction in terms of major cardiovascular events have been<br />reported from both observational and clinical studies. As a precaution, concomitant use of<br />omeprazole or esomeprozole should be discouraged (see section 4.4). No conclusive data on</p><p>the pharmacodynamic interaction of clopidogrel and other PPIs are available.<br />There is no evidence that other medicinal products that reduce stomach acid such as H2<br />blockers (except cimetidine which is a CYP2C19 inhibitor) or antacids interfere with<br />antiplatelet activity of clopidogrel.<br />Other medicinal products:<br />A number of other clinical studies have been conducted with clopidogrel and other<br />concomitant medicinal products to investigate the potential for pharmacodynamic and<br />pharmacokinetic interactions. No clinically significant pharmacodynamic interactions were<br />observed when clopidogrel was co-administered with atenolol, nifedipine, or both atenolol<br />and nifedipine.<br />Furthermore, the pharmacodynamic activity of clopidogrel was not significantly influenced<br />by the coadministration of phenobarbital or oestrogen.<br />The pharmacokinetics of digoxin or theophylline were not modified by the co-administration<br />of clopidogrel. Antacids did not modify the extent of clopidogrel absorption.<br />Data from studies with human liver microsomes indicated that the carboxylic acid metabolite<br />of clopidogrel could inhibit the activity of Cytochrome P450 2C9. This could potentially lead<br />to increased plasma levels of medicinal products such as phenytoin and tolbutamide and the<br />NSAIDs, which are metabolised by Cytochrome P450 2C9. Data from the CAPRIE study<br />indicate that phenytoin and tolbutamide can be safely co-administered with clopidogrel.<br />Apart from the specific medicinal product interaction information described above,<br />interaction studies with clopidogrel and some medicinal products commonly administered in<br />patients with atherothrombotic disease have not been performed. However, patients entered<br />into clinical trials with clopidogrel received a variety of concomitant medicinal products</p><p>including diuretics, beta blockers, ACEI, calcium antagonists, cholesterol lowering agents,<br />coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents and<br />GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As no clinical data on exposure to clopidogrel during pregnancy are available, it is preferable<br />not to use clopidogrel during pregnancy as a precautionary measure.<br />Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy,<br />embryonal/foetal development, parturition or postnatal development (see section 5.3).<br />It is unknown whether clopidogrel is excreted in human breast milk. Animal studies have<br />shown excretion of clopidogrel in breast milk. As a precautionary measure, breast feeding<br />should not be continued during treatment with Paleta.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clopidogrel has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clopidogrel has been evaluated for safety in more than 42,000 patients who have participated<br />in clinical studies, including over 9,000 patients treated for 1 year or more. The clinically<br />relevant adverse reactions observed in the CAPRIE, CURE, CLARITY and COMMIT studies<br />are discussed below. Overall, clopidogrel 75 mg/day was comparable to ASA 325 mg/day in<br />CAPRIE regardless of age, gender and race. In addition to clinical studies experience, adverse<br />reactions have been spontaneously reported.</p><p>Bleeding is the most common reaction reported both in clinical studies as well as in<br />postmarketing experience where it was mostly reported during the first month of treatment.<br />In CAPRIE, in patients treated with either clopidogrel or ASA, the overall incidence of any<br />bleeding was 9.3%. The incidence of severe cases was 1.4% for clopidogrel and 1.6% for ASA.<br />In CURE, the major bleeding event rate for clopidogrel+ASA was dose-dependent on ASA<br />(&lt;100mg: 2.6%; 100-200mg: 3.5%; &gt;200mg: 4.9%) as was the major bleeding event rate for<br />placebo+ASA (&lt;100mg: 2.0%; 100-200mg: 2.3%; &gt;200mg: 4.0%). The risk of bleeding (lifethreatening,<br />major, minor, other) decreased during the course of the trial: 01 months<br />(clopidogrel: 9.6%; placebo: 6.6%), 13 months (clopidogrel: 4.5%; placebo: 2.3%), 36 months<br />(clopidogrel: 3.8%; placebo: 1.6%), 69 months (clopidogrel: 3.2%; placebo: 1.5%), 912<br />months (clopidogrel: 1.9%; placebo: 1.0%). There was no excess in major bleeds with<br />clopidogrel + ASA within 7 days after coronary bypass graft surgery in patients who stopped<br />therapy more than five days prior to surgery (4.4% clopidogrel+ASA vs. 5.3% placebo+ASA).<br />In patients who remained on therapy within five days of bypass graft surgery, the event rate<br />was 9.6% for clopidogrel+ASA, and 6.3% for placebo+ASA.<br />In CLARITY, there was an overall increase in bleeding in the clopidogrel + ASA group<br />(17.4%) vs. the placebo + ASA group (12.9%).The incidence of major bleeding was similar<br />between groups (1.3% versus 1.1% for the clopidogrel + ASA and the placebo + ASA groups,<br />respectively). This was consistent across subgroups of patients defined by baseline<br />characteristics, and type of fibrinolytic or heparin therapy.<br />In COMMIT, the overall rate of noncerebral major bleeding or cerebral bleeding was low and<br />similar in both groups (0.6% versus 0.5% in the clopidogrel + ASA and the placebo + ASA<br />groups, respectively).<br />Adverse reactions that occurred either during clinical studies or that were spontaneously<br />reported are presented in the table below. Their frequency is defined using the following</p><p>conventions: common (1/100 to &lt;1/10); uncommon (1/1,000 to &lt;1/100); rare (1/10,000 to<br />&lt;1/1,000); very rare (&lt;1/10,000). Within each system organ class, adverse drug reactions are<br />presented in order of decreasing seriousness.</p><table border="1" cellspacing="1" cellpadding="1" style="width:581px"><tbody><tr><td style="width:127px"><strong>System Organ<br />Class</strong></td><td style="width:96px"><strong>Common</strong></td><td style="width:105px"><strong>Uncommon</strong></td><td style="width:111px"><strong>Rare</strong></td><td style="width:139px"><strong>Very rare</strong></td></tr><tr><td style="width:127px">Blood and the<br />lymphatic<br />system disorders</td><td style="width:96px">&nbsp;</td><td style="width:105px">Thrombocytopenia,<br />leucopenia,<br />eosinophilia</td><td style="width:111px">Neutropenia,<br />including<br />severe<br />neutropenia</td><td style="width:139px">Thrombotic<br />thrombocytopenic<br />purpura (TTP) (see<br />section 4.4),<br />aplastic anaemia,<br />pancytopenia,<br />agranulocytosis,<br />severe<br />thrombocytopenia,<br />granulocytopenia,<br />anaemia</td></tr><tr><td style="width:127px">Immune system<br />disorders</td><td style="width:96px">&nbsp;</td><td style="width:105px">&nbsp;</td><td style="width:111px">&nbsp;</td><td style="width:139px">Serum sickness,<br />anaphylactoid<br />reactions</td></tr><tr><td style="width:127px">Psychiatric<br />disorders</td><td style="width:96px">&nbsp;</td><td style="width:105px">&nbsp;</td><td style="width:111px">&nbsp;</td><td style="width:139px">Hallucinations,<br />confusion</td></tr><tr><td style="width:127px">Nervous system<br />disorders</td><td style="width:96px">&nbsp;</td><td style="width:105px">Intracranial<br />bleeding (some<br />cases were<br />reported with fatal&nbsp;outcome),<br />headache,<br />paraesthesia,<br />dizziness</td><td style="width:111px">&nbsp;</td><td style="width:139px">Taste disturbances</td></tr><tr><td style="width:127px">Eye disorders</td><td style="width:96px">&nbsp;</td><td style="width:105px">Eye bleeding<br />(conjunctival,<br />ocular, retinal)</td><td style="width:111px">&nbsp;</td><td style="width:139px">&nbsp;</td></tr><tr><td style="width:127px">Ear and<br />labyrinth<br />disorders</td><td style="width:96px">&nbsp;</td><td style="width:105px">&nbsp;</td><td style="width:111px">Vertigo</td><td style="width:139px">&nbsp;</td></tr><tr><td style="width:127px">Vascular<br />disorders</td><td style="width:96px">Haematoma</td><td style="width:105px">&nbsp;</td><td style="width:111px">&nbsp;</td><td style="width:139px">Serious<br />haemorrhage,<br />haemorrhage of<br />operative wound,<br />vasculitis,<br />hypotension</td></tr><tr><td style="width:127px">Respiratory,<br />thoracic and<br />mediastinal<br />disorders</td><td style="width:96px">Epistaxis</td><td style="width:105px">&nbsp;</td><td style="width:111px">&nbsp;</td><td style="width:139px">Respiratory tract<br />bleeding<br />(haemoptysis,<br />pulmonary<br />haemorrhage),<br />bronchospasm,<br />interstitial<br />pneumonitis</td></tr><tr><td style="width:127px">Gastrointestinal&nbsp;disorders</td><td style="width:96px">Gastrointestinal&nbsp;haemorrhage,<br />diarrhoea,<br />abdominal<br />pain, dyspepsia</td><td style="width:105px">Gastric ulcer and&nbsp;duodenal ulcer,<br />gastritis, vomiting,<br />nausea,<br />constipation,<br />flatulence</td><td style="width:111px">Retroperitoneal&nbsp;haemorrhage</td><td style="width:139px">Gastrointestinal and&nbsp;retroperitoneal<br />haemorrhage with<br />fatal outcome,<br />pancreatitis, colitis<br />(including<br />ulcerative or<br />lymphocytic<br />colitis), stomatitis</td></tr><tr><td style="width:127px">Hepato-biliary<br />disorders</td><td style="width:96px">&nbsp;</td><td style="width:105px">&nbsp;</td><td style="width:111px">&nbsp;</td><td style="width:139px">Acute liver failure,<br />hepatitis, abnormal<br />liver function test</td></tr><tr><td style="width:127px">Skin and<br />subcutaneous<br />tissue disorders</td><td style="width:96px">Bruising</td><td style="width:105px">Rash, pruritus, skin<br />bleeding (purpura)</td><td style="width:111px">&nbsp;</td><td style="width:139px">Bullous dermatitis<br />(toxic epidermal<br />necrolysis, Stevens<br />Johnson Syndrome,<br />erythema<br />multiforme),<br />angioedema, rash<br />erythematous,<br />urticaria, eczema,<br />lichen planus</td></tr><tr><td style="width:127px">Musculoskeletal,<br />connective<br />tissue and bone<br />disorders</td><td style="width:96px">&nbsp;</td><td style="width:105px">&nbsp;</td><td style="width:111px">&nbsp;</td><td style="width:139px">Musculoskeletal<br />bleeding<br />(haemarthrosis),<br />arthritis, arthralgia,<br />myalgia</td></tr><tr><td style="width:127px">Renal and<br />urinary disorders</td><td style="width:96px">&nbsp;</td><td style="width:105px">Haematuria</td><td style="width:111px">&nbsp;</td><td style="width:139px">Glomerulonephritis,<br />blood creatinine<br />increased</td></tr><tr><td style="width:127px">General<br />disorders and<br />administration<br />site conditions</td><td style="width:96px">Bleeding at<br />puncture site</td><td style="width:105px">&nbsp;</td><td style="width:111px">&nbsp;</td><td style="width:139px">Fever</td></tr><tr><td style="width:127px">nvestigations</td><td style="width:96px">&nbsp;</td><td style="width:105px">Bleeding time<br />prolonged,<br />neutrophil count<br />decreased, platelet<br />count decreased</td><td style="width:111px">&nbsp;</td><td style="width:139px">&nbsp;</td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Overdose following clopidogrel administration may lead to prolonged bleeding time and<br />subsequent bleeding complications. Appropriate therapy should be considered if bleedings are<br />observed.<br />No antidote to the pharmacological activity of clopidogrel has been found. If prompt correction<br />of prolonged bleeding time is required, platelet transfusion may reverse the effects of<br />clopidogrel.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>- Anatomical Therapeutical Chemical (ATC)</strong>: B01AC04.<br /><em><strong>- Pharmacotherapeutic group:</strong></em></p><p>Clopidogrel is a prodrug, one of whose metabolites is an inhibitor of platelet aggregation.<br />Clopidogrel must be metabolised by CYP450 enzymes to produce the active metabolite that<br />inhibits platelet aggregation. The active metabolite of clopidogrel selectively inhibits the<br />binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent<br />ADPmediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet<br />aggregation. Due to the irreversible binding, platelets exposed are affected for the remainder of<br />their lifespan (approximately 7-10 days) and recovery of normal platelet function occurs at a<br />rate consistent with platelet turnover. Platelet aggregation induced by agonists other than ADP<br />is also inhibited by blocking the amplification of platelet activation by released ADP.<br />Because the active metabolite is formed by CYP450 enzymes, some of which are polymorphic<br />or subject to inhibition by other drugs, not all patients will have adequate platelet inhibition.<br />Repeated doses of 75 mg per day produced substantial inhibition of ADP-induced platelet<br />aggregation from the first day; this increased progressively and reached steady state between<br />Day 3 and Day 7. At steady state, the average inhibition level observed with a dose of 75 mg<br />per day was between 40% and 60%. Platelet aggregation and bleeding time gradually returned<br />to baseline values, generally within 5 days after treatment was discontinued.<br />The safety and efficacy of clopidogrel have been evaluated in 4 double-blind studies involving<br />over 80,000 patients: the CAPRIE study, a comparison of clopidogrel to ASA, and the CURE,<br />CLARITY and COMMIT studies comparing clopidogrel to placebo, both medicinal products<br />given in combination with ASA and other standard therapy.<br />Recent myocardial infarction (MI), recent stroke or established peripheral arterial disease<br />The CAPRIE study included 19,185 patients with atherothrombosis as manifested by recent<br />myocardial infarction (&lt;35 days), recent ischaemic stroke (between 7 days and 6 months) or<br />established peripheral arterial disease (PAD). Patients were randomised to clopidogrel 75<br />mg/day or ASA 325 mg/day, and were followed for 1 to 3 years.</p><p>In the myocardial infarction subgroup, most of the patients received ASA for the first few days<br />following the acute myocardial infarction.<br />Clopidogrel significantly reduced the incidence of new ischaemic events (combined end point<br />of myocardial infarction, ischaemic stroke and vascular death) when compared to ASA. In the<br />intention to treat analysis, 939 events were observed in the clopidogrel group and 1,020 events<br />with ASA (relative risk reduction (RRR) 8.7%, [95% CI: 0.2 to 16.4]; p = 0.045), which<br />corresponds, for every 1000 patients treated for 2 years, to 10 [CI: 0 to 20] additional patients<br />being prevented from experiencing a new ischaemic event. Analysis of total mortality as a<br />secondary endpoint did not show any significant difference between clopidogrel (5.8%) and<br />ASA (6.0%).<br />In a subgroup analysis by qualifying condition (myocardial infarction, ischaemic stroke, and<br />PAD) the benefit appeared to be strongest (achieving statistical significance at p = 0.003) in<br />patients enrolled due to PAD (especially those who also had a history of myocardial infarction)<br />(RRR = 23.7%; CI: 8.9 to 36.2) and weaker (not significantly different from ASA) in stroke<br />patients (RRR = 7.3%; CI: -5.7 to 18.7 [p=0.258]). In patients who were enrolled in the trial on<br />the sole basis of a recent myocardial infarction, clopidogrel was numerically inferior, but not<br />statistically different from ASA (RRR = -4.0%; CI: -22.5 to 11.7 [p=0.639]). In addition, a<br />subgroup analysis by age suggested that the benefit of clopidogrel in patients over 75 years was<br />less than that observed in patients 75 years.<br />Since the CAPRIE trial was not powered to evaluate efficacy of individual subgroups, it is not<br />clear whether the differences in relative risk reduction across qualifying conditions are real, or<br />a result of chance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption</strong></p><p>After repeated oral doses of 75 mg per day, clopidogrel is rapidly absorbed. Mean peak plasma<br />levels of unchanged clopidogrel (approximately 2.2-2.5 ng/ml after a single 75 mg oral dose)<br />occurred approximately 45 minutes after dosing. Absorption is at least 50%, based on urinary<br />excretion of clopidogrel metabolites.<br /><strong>Distribution</strong><br />Clopidogrel and the main circulating (inactive) metabolite bind reversibly in vitro to human<br />plasma proteins (98% and 94% respectively). The binding is non-saturable in vitro over a wide<br />concentration range.<br /><strong>Biotransformation</strong><br />Clopidogrel is extensively metabolised by the liver. In vitro and in vivo, clopidogrel is<br />metabolised according to two main metabolic pathways: one mediated by esterases and leading<br />to hydrolysis into its inactive carboxylic acid derivative (85% of circulating metabolites), and<br />one mediated by multiple cytochromes P450. Clopidogrel is first metabolised to a 2-oxoclopidogrel<br />intermediate metabolite. Subsequent metabolism of the 2-oxo-clopidogrel<br />intermediate metabolite results in formation of the active metabolite, a thiol derivative of<br />clopidogrel. In vitro, this metabolic pathway is mediated by CYP3A4, CYP2C19, CYP1A2 and<br />CYP2B6. The active thiol metabolite which has been isolated in vitro, binds rapidly and<br />irreversibly to platelet receptors, thus inhibiting platelet aggregation.<br /><strong>Elimination</strong><br />Following an oral dose of 14C-labelled clopidogrel in man, approximately 50% was excreted in<br />the urine and approximately 46% in the faeces in the 120-hour interval after dosing. After a<br />single oral dose of 75 mg, clopidogrel has a half-life of approximately 6 hours. The elimination<br />half-life of the main circulating (inactive) metabolite was 8 hours after single and repeated<br />administration.</p><p><em>Pharmacogenetics</em><br />Several polymorphic CYP450 enzymes activate clopidogrel. CYP2C19 is involved in the<br />formation of both the active metabolite and the 2-oxo-clopidogrel intermediate metabolite.<br />Clopidogrel active metabolite pharmacokinetics and antiplatelet effects, as measured by ex vivo<br />platelet aggregation assays, differ according to CYP2C19 genotype. The CYP2C19*1 allele<br />corresponds to fully functional metabolism while the CYP2C19*2 and CYP2C19*3 alleles<br />correspond to reduced metabolism. The CYP2C19*2 and CYP2C19*3 alleles account for 85%<br />of reduced function alleles in whites and 99% in Asians. Other alleles associated with reduced<br />metabolism include CYP2C19*4, *5, *6, *7, and *8, but these are less frequent in the general<br />population. Published frequencies for the common CYP2C19 phenotypes and genotypes are<br />listed in the table below.<br /><strong>CYP2C19 Phenotype and Genotype Frequency<br />Frequency (<em>%</em>)</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:559px"><tbody><tr><td style="width:137px">&nbsp;</td><td style="width:137px">White (n=1356)</td><td style="width:126px">Black (n=966)</td><td style="width:157px">Chinese<br />(n=573)</td></tr><tr><td style="width:137px">Extensive metabolism:<br />CYP2C19*1/*1</td><td style="width:137px">74</td><td style="width:126px">66</td><td style="width:157px">38</td></tr><tr><td style="width:137px">Intermediate metabolism:<br />CYP2C19*1/*2 or *1/*3</td><td style="width:137px">26</td><td style="width:126px">29</td><td style="width:157px">50</td></tr><tr><td style="width:137px">Poor metabolism: CYP2C19*2/*2,<br />*2/*3 or *3/*3</td><td style="width:137px">2</td><td style="width:126px">4</td><td style="width:157px">14</td></tr></tbody></table><p>To date, the impact of CYP2C19 genotype on the pharmacokinetics of the active metabolite of<br />clopidogrel has been evaluated in 227 subjects from 7 reported studies. Reduced CYP2C19<br />metabolism in intermediate and poor metabolisers decreased the Cmax and AUC of the active<br />metabolite by 30-50% following 300- or 600mg loading doses and 75mg maintenance doses.<br />Lower active metabolite exposure results in less platelet inhibition or higher residual platelet<br />reactivity. To date, diminished antiplatelet responses to clopidogrel have been described for<br />intermediate and poor metabolisers in 21 reported studies involving 4,520 subjects. The<br />relative difference in antiplatelet response between genotype groups varies across studies<br />depending on the method used to evaluate response, but is typically greater than 30%. The<br />association between CYP2C19 genotype and clopidogrel treatment outcome was evaluated in 2<br />post hoc clinical trial analyses (substudies of CLARITY [n=465] and TRITON-TIMI 38<br />[n=1,477]) and 5 cohort studies (total n=6,489). In CLARITY and one of the cohort studies<br />(n=765; Trenk), cardiovascular event rates did not differ significantly by genotype. In<br />TRITON-TIMI 38 and 3 of the cohort studies (n= 3,516; Collet, Sibbing, Giusti), patients with<br />an impaired metaboliser status (intermediate and poor combined) had a higher rate of<br />cardiovascular events (death, myocardial infarction, and stroke) or stent thrombosis compared<br />to extensive metabolisers. In the fifth cohort study (n=2,208; Simon), the increased event rate<br />was observed only in poor metabolisers.<br />Pharmacogenetic testing can identify genotypes associated with variability in CYP2C19<br />activity.<br />There may be genetic variants of other CYP450 enzymes with effects on the ability to form the<br />active metabolite of clopidogrel.<br /><u>Special populations</u><br />The pharmacokinetics of the active metabolite of clopidogrel is not known in these special<br />populations.</p><p><em>Renal impairment</em><br />After repeated doses of 75 mg clopidogrel per day in subjects with severe renal disease<br />(creatinine clearance from 5 to 15 ml/min) compared inhibition of ADP-induced platelet<br />aggregation was lower (25%) than that observed in healthy subjects, however, the prolongation<br />of bleeding time was similar to that seen in healthy subjects receiving 75 mg of clopidogrel per<br />day. In addition, clinical tolerance was good in all patients.<br /><em>Hepatic impairment</em><br />After repeated doses of 75 mg clopidogrel per day for 10 days in patients with severe hepatic<br />impairment, inhibition of ADP- induced platelet aggregation was similar to that observed in<br />healthy subjects. The mean bleeding time prolongation was also similar in the two groups.<br /><em>Race</em><br />The prevalence of CYP2C19 alleles that result in intermediate and poor CYP2C19 metabolism<br />differs according to race/ethnicity (see Pharmacogenetics). From literature, limited data in<br />Asian populations are available to assess the clinical implication of genotyping of this CYP on<br />clinical outcome events.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>During non clinical studies in rat and baboon, the most frequently observed effects were liver<br />changes. These occurred at doses representing at least 25 times the exposure seen in humans<br />receiving the clinical dose of 75 mg/day and were a consequence of an effect on hepatic<br />metabolising enzymes. No effect on hepatic metabolising enzymes was observed in humans<br />receiving clopidogrel at the therapeutic dose.</p><p>At very high doses, a poor gastric tolerability (gastritis, gastric erosions and/or vomiting) of<br />clopidogrel was also reported in rat and baboon.<br />There was no evidence of carcinogenic effect when clopidogrel was administered for 78 weeks<br />to mice and 104 weeks to rats when given at doses up to 77 mg/kg per day (representing at<br />least 25 times the exposure seen in humans receiving the clinical dose of 75 mg/day).<br />Clopidogrel has been tested in a range of in vitro and in vivo genotoxicity studies, and showed<br />no genotoxic activity.<br />Clopidogrel was found to have no effect on the fertility of male and female rats and was not<br />teratogenic in either rats or rabbits. When given to lactating rats, clopidogrel caused a slight<br />delay in the development of the offspring. Specific pharmacokinetic studies performed with<br />radiolabelled clopidogrel have shown that the parent compound or its metabolites are excreted<br />in the milk. Consequently, a direct effect (slight toxicity), or an indirect effect (low<br />palatability) cannot be excluded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cellulose microcrystalline, Spray-dried Mannitol (Mannogem EZ), Hydroxypropylcellulose,<br />Crospovidone,Citric acid, Polyethylene glycol 6000, Stearic acid (Speziol L2SM), Talc,<br />OpadryIIPink 32K14834.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not Applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Blister packed consisting PA/ALL/PVC reel and hard tampered Aluminium Foil lid.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SPIMACO
AlQassim pharmaceutical plant
Saudi Pharmaceutical Industries &
Medical Appliance Corporation.
Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                May 2012.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>